OCULAR THERAPEUTIX ($OCUL) posted quarterly earnings results for Q1 2026 on Tuesday, May 5th. The company reported earnings of -$0.41 per share, missing estimates of -$0.32 by $0.09. The company also reported revenue of $10,790,000, missing estimates of $12,851,071 by $-2,061,071.
You can see Quiver Quantitative's $OCUL stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
OCULAR THERAPEUTIX Insider Trading Activity
OCULAR THERAPEUTIX insiders have traded $OCUL stock on the open market 13 times in the past 6 months. Of those trades, 1 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $OCUL stock by insiders over the last 6 months:
- PRAVIN DUGEL (See Remarks) has made 0 purchases and 2 sales selling 144,938 shares for an estimated $1,294,996.
- RICHARD L MD LINDSTROM purchased 60,229 shares for an estimated $461,354
- NAMRATA SAROJ (Chief Business Officer) sold 25,865 shares for an estimated $277,790
- DONALD NOTMAN (Chief Operating Officer) has made 0 purchases and 3 sales selling 22,936 shares for an estimated $204,869.
- SANJAY NAYAK (Chief Strategy Officer) has made 0 purchases and 2 sales selling 12,107 shares for an estimated $108,110.
- NADIA WAHEED (Chief Medical Officer) has made 0 purchases and 2 sales selling 11,373 shares for an estimated $98,248.
- JEFFREY S. HEIER (Chief Scientific Officer) sold 3,057 shares for an estimated $25,311
- PETER KAISER (Chief Development Officer) sold 2,810 shares for an estimated $23,266
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
OCULAR THERAPEUTIX Hedge Fund Activity
We have seen 161 institutional investors add shares of OCULAR THERAPEUTIX stock to their portfolio, and 90 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VR ADVISER, LLC removed 5,845,915 shares (-44.4%) from their portfolio in Q4 2025, for an estimated $70,969,408
- BLACKROCK, INC. added 5,045,557 shares (+47.8%) to their portfolio in Q4 2025, for an estimated $61,253,061
- DEEP TRACK CAPITAL, LP removed 3,861,723 shares (-32.4%) from their portfolio in Q4 2025, for an estimated $46,881,317
- POINT72 ASSET MANAGEMENT, L.P. removed 3,585,073 shares (-77.9%) from their portfolio in Q4 2025, for an estimated $43,522,786
- CITADEL ADVISORS LLC removed 3,227,932 shares (-56.6%) from their portfolio in Q4 2025, for an estimated $39,187,094
- VANGUARD GROUP INC added 2,411,953 shares (+26.3%) to their portfolio in Q4 2025, for an estimated $29,281,109
- JANUS HENDERSON GROUP PLC added 2,180,702 shares (+106.5%) to their portfolio in Q4 2025, for an estimated $26,473,722
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
OCULAR THERAPEUTIX Analyst Ratings
Wall Street analysts have issued reports on $OCUL in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Clear Street issued a "Buy" rating on 03/03/2026
- Chardan Capital issued a "Buy" rating on 02/18/2026
- HC Wainwright & Co. issued a "Buy" rating on 11/25/2025
To track analyst ratings and price targets for OCULAR THERAPEUTIX, check out Quiver Quantitative's $OCUL forecast page.
OCULAR THERAPEUTIX Price Targets
Multiple analysts have issued price targets for $OCUL recently. We have seen 4 analysts offer price targets for $OCUL in the last 6 months, with a median target of $21.0.
Here are some recent targets:
- Yi Chen from HC Wainwright & Co. set a target price of $21.0 on 04/13/2026
- Bill Maughan from Clear Street set a target price of $28.0 on 03/03/2026
- Serge Belanger from Needham set a target price of $18.0 on 02/20/2026
- Daniil Gataulin from Chardan Capital set a target price of $21.0 on 02/18/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
